Navigation Links
Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
Date:1/26/2009

Article in Gynecologic Oncology Supports Use of Fujirebio Diagnostics'

HE4 Test with CA125 for Risk Stratification of Women with Suspected Ovarian Cancer

MALVERN, Pa., Jan. 26 /PRNewswire/ -- A pivotal clinical trial published in the January 2009 issue of the journal Gynecologic Oncology demonstrated the utility of combining Fujirebio Diagnostics' HE4 and the CA125 test as an aid in estimating the risk of epithelial ovarian cancer in premenopausal or postmenopausal women presenting with pelvic mass. The HE4 test, which is under review by the U.S. Food and Drug Administration (FDA), was reported to successfully stratify patients into high- and low-risk groups when combined with CA125.

The combination test uses the results from two simple blood tests - CA125 and HE4 - and the Risk of Ovarian Malignancy Algorithm (ROMA(TM)) to identify patients at a high risk of having ovarian cancer. CA125 is the current gold standard for monitoring patients diagnosed with ovarian cancer. The HE4 assay was recently cleared by the FDA as an aid for monitoring recurrence of epithelial ovarian cancer (EOC), the most common type of ovarian cancer. Combining the HE4 and CA125 tests may enable physicians to pre-operatively identify those patients with a high risk of malignancy.

"Research suggests that ovarian cancer patients have better outcomes and improved survival when treated by gynecologic oncologists, surgeons that are trained and specialize in the treatment of patients with EOC," said Richard G. Moore, MD, Director of Medical Education, Program in Women's Oncology at Women and Infants' Hospital, and Assistant Professor, Obstetrics and Gynecology, Brown University, Providence, R.I, and lead author of the Gynecologic Oncology paper. "Combining measurements of HE4 and CA125 helps us to identify women who are at high risk of ovarian cancer when they present with an ovarian cyst or mass. T
'/>"/>

SOURCE Fujirebio Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
4. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
5. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
6. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
9. Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD
10. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
11. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Capecitabine More Than Doubles Time to Progression and Overall Response ... + Placebo in Patients with 2nd or 3rd Line Metastatic ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) yesterday announced ... Akt-inhibitor for cancer, in combination with capecitabine as a treatment ...
... , New study finds patients who opt for surgery have decreased ... People with the spine disease called degenerative spondylolisthesis ... from pain over time compared to those who do not have ... of The Journal of Bone and Joint Surgery ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4
(Date:7/10/2014)... far outweigh the risks when children receive The Right ... Dose. However, overuse and misuse of imaging change the ... effort to ensure a national protocol is put into ... of Patient Safety , calls for the American College ... and the Centers for Medicare & Medicaid Services to ...
(Date:7/10/2014)... more severe illness and even death are likely to ... developing influenza. Now, however, a team of researchers based ... reverse the order of infection, the bacteria Streptococcus ... a bad case of the flu. , The ... described as a bacterial virulence factor, might protect macrophagesa ...
(Date:7/10/2014)... Rutgers University-Newark says the human brain operates much the ... that could provide a better understanding of schizophrenia, bipolar ... an estimated 13.6 million Americans. , In newly published ... an assistant professor at the Center for Molecular and ... a person at rest is basically the same as ...
(Date:7/10/2014)... with localized prostate cancer were more likely to ... less effective treatments and survived for shorter times ... a UCLA study has found. , The negative ... such as bias against the mentally ill, depression,s ... lack of investment in his general health and ...
(Date:7/10/2014)... are just as tempting as full-fat equivalents could ... insights into how proteins can replace fats without ... by the Engineering and Physical Sciences Research Council ... University of Edinburgh has produced modified proteins that ... mimic the behaviour of fats during food manufacture. ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Working to loosen the grip of severe mental illness 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2
... 5, 2008/Saranac Lake, N.Y.-- On May 12, 2008, the ... in their Distinguished Americans series. The stamp, the eleventh ... (1848-1915). Stamp collecting is one of the most popular ... 20 million American collectors participating in the activity. The ...
... PRINCETON, N.J., May 7 Patients, nurses,physicians and other ... on the State House May 12 to protest the ... 2009 state budget,plan., WHAT: "Care Today, Gone Tomorrow," ... House steps, West State Street, Trenton, WHEN: 12 ...
... from Caring.com Now Available to Thousands ... of Pennsylvanians Caring for an Aging Parent, ... to,announce a partnership with Trib Total Media, publisher of ... the,magazine,s new online companion. The new online resource,( http://pacaregiver.caring.com ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held May 13-15, 2008 at the ... CEO, and Walter Hosp, Chief Financial,Officer of HMS Holdings ... PT., HMS Holdings Corp. (Nasdaq: HMSY ) ...
... families in Mexico support innovations to extend the local, productive impact of remittances shines ... ... in Mexico and the US. - Broad, support in communities of origin for ... money from the US. -, Family members in Mexico would encourage senders ...
... leads $12 Million in Series A First Tranche Financing, ... NGN Capital announced,today the formation of ACT Biotech Inc., ... cancer drugs. ACT Biotech has,entered into a license agreement ... early stage oncology assets. In conjunction with the,agreement, ACT ...
Cached Medicine News:Health News:New United States Postal Service stamp honors an American scientist 2Health News:New United States Postal Service stamp honors an American scientist 3Health News:Caring.com Partners With Trib Total Media to Support the Development of a New Online Eldercare Resource 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare 2
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
The new Gemini EM microplate spectrofluorometer builds on the successful Gemini platform. This next generation reader incorporates all of the high performance features of the Gemini XS with new capab...
... DNA, RNA, Or Fluorescent Tags. Accurate quantitation of ... to life science research. The RF-Mini 150 Fluorometer ... as small as 1ng/ml of DNA specific Hoechst ... and emission filters, the RF-Mini 150 can measure ...
Medicine Products: